Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reiterates Buy Rating and Adjusts Price Target for Phreesia NYSE PHR

Elaine Mendonca by Elaine Mendonca
January 18, 2024
in Breaking News
0
Healthcare Services Stock Exchange
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

On January 18, 2024, Ryan MacDonald, an analyst at Needham, expressed his optimistic view on Phreesia (NYSE: PHR) by reiterating a Buy rating and maintaining a price target of $29. This reaffirmation of confidence in the company’s stock indicates the potential for upward movement. Although the price target has been adjusted from $40 to $29, the Buy recommendation showcases MacDonald’s belief in Phreesia’s future performance.

PHR Stock Performance Declines on January 18, 2024: A Detailed Analysis

PHR, a publicly traded company, experienced a decline in its stock performance on January 18, 2024. According to data sourced from CNN Money, the stock closed at $24.03, marking a decrease of $0.68 or 2.75% from the previous market close. Additionally, in after-hours trading, the stock dropped a further $0.20.

PHR Stock Performance on January 18, 2024: Mixed Revenue Growth and Net Income Decline

PHR Stock Performance on January 18, 2024: A Mixed Bag of Revenue Growth and Net Income Decline

On January 18, 2024, PHR stock experienced a mixed performance as the company’s revenue showed promising growth, while its net income declined.

Total revenue for PHR stood at $280.91 million for the past year, representing a substantial increase of 31.74% compared to the previous year. Additionally, the company’s total revenue also increased by 6.74% since the last quarter.

However, the picture is not entirely rosy, as PHR’s net income witnessed a decline. Over the past year, the company reported a net income of -$176.15 million, reflecting a decrease of 49.07% compared to the previous year. On a positive note, the net income increased by 13.13% since the last quarter.

The earnings per share (EPS) is another crucial metric to assess a company’s financial performance. PHR reported an EPS of -$3.36 for the past year, which is a decrease of 41.82% compared to the previous year. However, there was a slight improvement in the EPS since the last quarter, with a 15.42% increase.

Overall, the stock performance of PHR on January 18, 2024, showcased a mix of positive and negative indicators. While the company experienced significant revenue growth over the past year and quarter, the net income and EPS declined on a yearly basis. However, there was a slight improvement in net income and EPS since the last quarter, which may indicate that PHR is taking steps to address its profitability challenges.

Investors should carefully analyze these financial metrics and consider other factors, such as market conditions and industry trends, before making any investment decisions related to PHR stock. It is essential to assess the company’s long-term strategy, competitive positioning, and ability to adapt to changing market dynamics to make informed investment choices.

Tags: PHR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Retail Market Capitalization

Introducing Club92 Dollar Generals Exclusive Home Fragrance Collection

Technology Robotics Trading online

Analysts Provide Mixed Ratings and Price Targets for Impinj NASDAQPI

CTVA stock news

Mixed Analyst Sentiments and Price Targets for Adobe NASDAQ ADBE

Recommended

XRP Stock

XRP Faces Resistance as Rally Attempt Falters

2 months ago
Insurance company Stock Bull Market

Analyst Expresses Optimism Towards Travelers Companies and Allstate

2 years ago
Rheinmetall Stock

German Defense Giant Rheinmetall Poised for Major Air Defense Contract

4 months ago
Finance_Capitalistic

Top Stock Picks and Performance Analysis on CNBCs Halftime Report Final Trades

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Camping World’s New Leadership Faces First Major Test

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Trending

Boston Omaha Stock
Analysis

Investors Await March Report for Boston Omaha’s Strategic Direction

by SiterGedge
February 7, 2026
0

With no recent corporate announcements influencing its share price, market attention has shifted decisively to the upcoming...

Universal Insurance Stock

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Investors Await March Report for Boston Omaha’s Strategic Direction
  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com